Celldex Therapeutics Raises $250M Via Equity To Support Development Of Skin Disease Candidate

  • Celldex Therapeutics Inc CLDX has priced an underwritten public offering of around 5.9 million shares at $42.00 per share, representing a discount of about 6% from the last close price of $44.6 on Tuesday.
  • Gross proceeds are expected to approximately $250 million.
  • The Company previously announced to offer $175 million in shares.
  • Underwriters have an option to purchase up to an additional 892,857 shares.
  • Jefferies, SVB Leerink, Guggenheim Securities, and Cantor are acting as the joint book-running managers for the offering. 
  • LifeSci Capital LLC and H.C. Wainwright & Co. are acting as co-lead managers for the offering.
  • Celldex will use the proceeds to fund the development of CDX-0159 and for general corporate purposes.
  • The offering will close by July 16.
  • Recently, the Company shared positive Phase 1b trial data of CDX-0159 in patients with antihistamine refractory cold urticaria and symptomatic dermographism.
  • Price Action: CLDX shares are down 2.65% at $43.42 premarket on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFinancingOfferingsSmall CapGeneralBriefsSkin Disorder
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!